Stocktoria
Atara Biotherapeutics, Inc. ATRA
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2014-10-16
Atara Biotherapeutics, Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | 29.7% | -64.7% | -3219.5% | -441.2% | — |
| Net margin | 27.1% | -66.2% | -3220.9% | -359.1% | — |
| FCF margin | -42.2% | -53.5% | -2265.3% | -432.0% | — |
| Return on assets | 161.5% | -78.3% | -166.8% | -60.7% | -72.7% |
| Return on equity | -84.9% | 87.8% | -278.3% | -180.3% | -121.6% |
| Current ratio | 0.82 | 0.48 | 0.72 | 3.74 | 3.64 |
| Revenue growth | -6.3% | 1404.0% | -86.5% | — | — |
Source: SEC EDGAR filings · CIK 0001604464 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.